Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.
Agnese Maria FiorettiTiziana LeopizziAgata PuzzovivoFrancesco GiottaVito LorussoGiovanni LuzziStefano OlivaPublished in: International journal of clinical practice (2022)
Cancer-associated thrombosis (CAT) is the second main cause of cancer death with high related mortality and morbidity, leading to anticancer agent delays and interruptions. The recommended therapy, low-molecular-weight heparin (LMWH), however, is burdensome for patients and costly for society, as treatment should last until cancer is no longer active, even indefinitely. Tinzaparin is a manageable, efficient, safe, and cost-effective option. Compared to the other LMWHs, advantages are single-daily dose and safety in the elderly and those with renal impairment (RI). The purpose of this review is to critically discuss recent data on its efficacy and safety in CAT.
Keyphrases
- papillary thyroid
- end stage renal disease
- pulmonary embolism
- squamous cell
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- venous thromboembolism
- physical activity
- peritoneal dialysis
- type diabetes
- squamous cell carcinoma
- machine learning
- lymph node metastasis
- young adults
- mesenchymal stem cells
- growth factor
- cardiovascular disease
- coronary artery disease
- combination therapy
- community dwelling